AbbVie Inc ABBV:NYSE

RT Quote | Last NASDAQ LS, VOL From CTA | USD

Last | 05/16/24 EDT

164.35

+0.56 (+0.34%)

Volume

4,111,038

52 week range

130.96 - 182.89

Open0.00
Day High0.00
Day Low0.00
Prev Close164.35
52 Week High182.89
52 Week High Date03/12/24
52 Week Low130.96
52 Week Low Date06/28/23

Key Stats

Market Cap290.22B
Shares Out1.77B
10 Day Average Volume4.87M
Dividend6.20
Dividend Yield3.77%
Beta0.58
YTD % Change6.05

KEY STATS

Open0.00
Day High0.00
Day Low0.00
Prev Close164.35
52 Week High182.89
52 Week High Date03/12/24
52 Week Low130.96
52 Week Low Date06/28/23
Market Cap290.22B
Shares Out1.77B
10 Day Average Volume4.87M
Dividend6.20
Dividend Yield3.77%
Beta0.58
YTD % Change6.05

RATIOS/PROFITABILITY

EPS (TTM)3.36
P/E (TTM)48.95
Fwd P/E (NTM)14.72
EBITDA (TTM)24.771B
ROE (TTM)55.92%
Revenue (TTM)54.403B
Gross Margin (TTM)66.30%
Net Margin (TTM)11.04%
Debt To Equity (MRQ)924.20%

EVENTS

Earnings Date07/25/2024(est)
Ex Div Date04/12/2024
Div Amount1.55
Split Date-
Split Factor-

Latest On AbbVie Inc

Healthy Returns: Humira sales are plunging, but AbbVie has two successorsMay 1, 2024CNBC.com
Jim Cramer's quick thoughts on 5 stocks: Chevron, Snap, Intel, AbbVie and ColgateApril 26, 2024CNBC.com
Monday’s rapid fire: Chevron, Snap, Intel, Abbvie and ColgateApril 26, 2024CNBC.com
Stocks making the biggest moves premarket: Alphabet, Microsoft, Intel and moreApril 26, 2024CNBC.com
Can a new batch of tech earnings rescue the market? Here are the factors at playApril 25, 2024CNBC.com

Content From Our Affiliates

3 Best Value Stocks to Buy in May 2024, According to AnalystsMay 15, 2024TipRanks
Buy Rating Affirmed: AbbVie’s Promising Growth Trajectory and Financial OutlookMay 14, 2024TipRanks
AbbVie, Gilgamesh Pharmaceuticals to co-develop psychiatric disorder therapiesMay 13, 2024TipRanks
AbbVie price target lowered to $180 from $195 at BMO CapitalApril 29, 2024TipRanks
AbbVie price target lowered to $191 from $196 at Morgan StanleyApril 29, 2024TipRanks

Profile

AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of...

Richard Gonzalez

Executive Chairman of the Board

Robert Michael CPA

Chief Executive Officer, Director

Scott Reents

Chief Financial Officer, Executive Vice President

Perry Siatis

Executive Vice President, General Counsel, Company Secretary

Nicholas Donoghoe M.D.

Executive Vice President, Chief Business and Strategy Officer

Address

1 N Waukegan Rd

North Chicago, IL

60064

United States

https://www.abbvie.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
AZN AstraZeneca PLC	77.04	+0.07	+0.09%
MRK Merck & Co Inc	130.88	-0.85	-0.65%
NVS Novartis AG	102.69	-0.53	-0.51%
PFE Pfizer Inc	28.92	+0.10	+0.35%
RHHBY Roche Holding AG	32.65	+1.25	+3.98%